Table 1 Baseline characteristics of the study population by tertiles of TyG-BMI index
|  | Tertile 1 (n = 479) | Tertile 2 (n = 479) | Tertile 3 (n = 480) | P value |
|---|---|---|---|---|
Demographics | ||||
 Gender, female, (%) | 65 (13.6) | 167 (34.9) | 220 (45.8) |  < 0.001 |
 Age, years | 59.4 ± 11.4 | 60.5 ± 11.1 | 60.3 ± 10.7 | 0.254 |
 BMI, (Kg/m2) | 20.2 ± 2.1 | 23.7 ± 1.7 | 27.6 ± 2.9 |  < 0.001 |
Medical history | Â | Â | Â | Â |
 Heart failure, (%) | 51 (10.6) | 46 (9.6) | 61 (12.7) | 0.294 |
 Atrial fibrillation, (%) | 13 (2.7) | 8 (1.7) | 4 (0.8) | 0.083 |
 Previous AMI, (%) | 49 (10.2) | 39 (8.1) | 41 (8.5) | 0.487 |
 Previous stroke, (%) | 24 (5) | 21 (4.4) | 18 (3.8) | 0.635 |
 Previous PCI, (%) | 32 (6.7) | 24 (5) | 24 (5) | 0.429 |
 Hypertension, (%) | 175 (36.5) | 235 (49.1) | 309 (64.4) |  < 0.001 |
 Diabetes mellitus, (%) | 66 (13.8) | 105 (21.9) | 157 (32.7) |  < 0.001 |
 Smoking, (%) | 212 (44.3) | 143 (29.9) | 138 (28.7) |  < 0.001 |
Clinical presentation | Â | Â | Â | 0.001 |
 SA, (%) | 58 (12.1) | 56 (11.7) | 59 (12.3) |  |
 NSTE-ACS, (%) | 265 (55.3) | 313 (65.3) | 316 (65.8) |  |
 STEMI, (%) | 156 (32.6) | 110 (23) | 105 (21.9) |  |
 LVEF, (%) | 60.3 ± 7.4 | 61.0 ± 7.4 | 62.0 ± 6.9 | 0.011 |
Laboratory data | Â | Â | Â | Â |
 Glycemia, mmol/L (IQR) | 5.0 (4.6, 5.7) | 5.2 (4.7, 6.3) | 5.8 (5.0, 7.6) |  < 0.001 |
 Creatinine, umol/L (IQR) | 71.0 (61.0, 85.0) | 69.0 (57.0, 81.0) | 66.0 (55.0, 80.0) |  < 0.001 |
 Uric acid, umol/L (IQR) | 302.0 (246.8, 355.0) | 291.0 (244.5, 354.0) | 298.0 (240.2, 356.0) | 0.669 |
 Bilirubin, umol/L (IQR) | 8.3 (5.9, 11.6) | 8.6 (5.8, 12.2) | 8.8 (5.9, 11.7) | 0.791 |
 TG, mmol/L (IQR) | 4.0 (3.4, 4.7) | 4.1 (3.5, 4.8) | 4.5 (3.8, 5.2) |  < 0.001 |
 TC, mmol/L (IQR) | 1.3 (1.0, 1.8) | 1.5 (1.2, 2.1) | 2.2 (1.5, 3.0) |  < 0.001 |
 HDL-C, mmol/L (IQR) | 1.1 (0.9, 1.3) | 1.0 (0.9, 1.2) | 1.0 (0.8, 1.2) |  < 0.001 |
 LDL-C, mmol/L (IQR) | 2.6 (2.0, 3.2) | 2.6 (2.0, 3.3) | 2.8 (2.2, 3.5) |  < 0.001 |
Treatment | Â | Â | Â | Â |
 Aspirin, (%) | 476 (99.4) | 470 (98.3) | 470 (98.1) | 0.207 |
 Clopidogrel, (%) | 460 (96) | 460 (96) | 470 (97.9) | 0.172 |
 Beta blocker, (%) | 325 (67.8) | 348 (72.7) | 329 (68.5) | 0.217 |
 ACEI, (%) | 247 (51.6) | 282 (58.9) | 309 (64.5) |  < 0.001 |
 CCB, (%) | 79 (16.5) | 121 (25.3) | 152 (31.7) |  < 0.001 |
 Statin, (%) | 450 (93.9) | 452 (94.4) | 441 (91.9) | 0.251 |
 Radial artery access, (%) | 468 (97.7) | 467 (97.5) | 471 (98.1) | 0.797 |
 Number of diseased vessels, (%) |  |  |  | 0.098 |
 1-vessel disease | 200 (41.8) | 168 (35.1) | 163 (34) |  |
 2-vessel disease | 173 (36.1) | 184 (38.4) | 190 (39.6) |  |
 3-vessel disease | 106 (22.1) | 127 (26.5) | 127 (26.5) |  |
Location of target lesions | Â | Â | Â | Â |
 LM, (%) | 19 (4) | 17 (3.5) | 10 (2.1) | 0.22 |
 LAD, (%) | 396 (82.7) | 414 (86.4) | 393 (81.9) | 0.126 |
 LCX, (%) | 232 (48.4) | 233 (48.6) | 245 (51) | 0.668 |
 RCA, (%) | 217 (45.3) | 250 (52.2) | 260 (54.2) | 0.016 |
Characteristics of lesions | Â | Â | Â | Â |
 Occlusion, (%) | 69 (14.4) | 62 (12.9) | 64 (13.3) | 0.791 |
 CTO, (%) | 41 (8.6) | 48 (10) | 31 (6.5) | 0.134 |
 Ostial lesion, (%) | 72 (15) | 48 (10) | 50 (10.4) | 0.028 |
 Bifurcation lesion, (%) | 99 (20.7) | 72 (15) | 78 (16.2) | 0.053 |
Number of treated vessels, (%) | Â | Â | Â | 0.028 |
 1 | 303 (63.3) | 269 (56.2) | 261 (54.4) |  |
 2 | 133 (27.8) | 166 (34.7) | 179 (37.3) |  |
  ≥ 3 | 43 (9) | 44 (9.2) | 40 (8.3) |  |
Number of stents, (%) | Â | Â | Â | 0.042 |
 1 | 209 (43.6) | 188 (39.2) | 168 (35) |  |
 2 | 146 (30.5) | 143 (29.9) | 149 (31) |  |
  ≥ 3 | 124 (25.9) | 148 (30.9) | 163 (34) |  |
Length of stents, (mm) | 46.1 ± 29.7 | 49.3 ± 33.2 | 51.1 ± 30.9 | 0.041 |
Diameter of stents, (mm) | 3.2 ± 1.3 | 3.1 ± 1.3 | 3.1 ± 0.4 | 0.387 |